New Report Reveals Deep Social Inequities in Counties Hard Hit by Alzheimer’s Disease Among Blacks and Latinos
Report from UsAgainstAlzheimer’s and Urban Institute highlights the importance of addressing the social determinants of health in race to cure and prevent Alzheimer's
Aducanumab and UsAgainstAlzheimer’s
Aducanumab is a proposed treatment for early Alzheimer’s disease that is intended to slow the progression of the disease. UsAgainstAlzheimer’s (UsA2) has urged the U.S. Food and Drug Administration to approve aducanumab.
2020 UsAgainstAlzheimer's National Alzheimer's Summit Highlight Reel
UsAgainstAlzheimer's National Alzheimer's Summit October 19 — October 21, 2020.
UsAgainstAlzheimer’s Statement on Exciting Development with New Blood Test to Help in Evaluating Patients for Alzheimer’s
UsAgainstAlzheimer’s issued the following statement by George Vradenburg, chairman and co-founder, on the announcement today by C2N Diagnostics of a new, more widely accessible blood test.
Being Patient: National Alzheimer’s Summit: How To Reduce Dementia Risk
At the National Alzheimer’s Summit, experts stressed that it is possible for people to reduce their risk of developing dementia by making certain lifestyle changes.
The 2020 National Alzheimer's Virtual Summit
Watch the 2020 National Alzheimer's Summit on demand.